Aldatu Selected for AdvaMed 2015 Innovation Showcase

Washington, DC, 18th September 2015 (download press release .pdf)

AdvaMed 2015: The MedTech Conference, the leading gathering of medical technology professionals in North America, has awarded 48 scholarships to early and development stage medical device, diagnostic and health IT companies to present at the conference in San Diego from October 5-7.

“Exposure at conferences like AdvaMed 2015 is crucial for early stage medical technology companies to reach key audiences like investors and strategic partners,” said Paul Grand, managing director of RCT Ventures and head of the MedTech Innovator accelerator. “The amazing opportunity for emerging companies to reach the industry influencers at AdvaMed 2015 is the reason Medtech Innovator is sponsoring Innovation Showcase scholarships for all twenty of our 2015 accelerator companies.”

Scholarship recipients will present during 12 interactive sessions on a special stage in the AdvaMed 2015 exhibit hall and will participate in a Strategic Investor Speed Dating event with leading corporate business development executives and active medical technology investors. They will also have the opportunity to host 1-on-1 partnering meetings and display marketing materials in the conference Partnering Zone.

“The Aldatu Biosciences team is delighted to be selected as one of 48 emerging medical technology companies to participate in AdvaMed 2015’s Innovation Showcase,” said David Raiser, Aldatu’s CEO. “We are so thankful to the National Institutes of Health for sponsoring our scholarship and look forward to joining more than 1,000 medical technology companies in attendance for networking, establishing capital partnerships, and more.”

The National Institutes of Health join 11 other organizations including Biocom, MedTech Innovator, BD, Johnson & Johnson, and RCT Ventures in providing scholarships that support the emerging medical technology companies in the Innovation Showcase. 48 winning companies hail from industry sectors including cardiovascular; patient monitoring; in vitro diagnostics; neurological, oncology, ophthalmic and orthopedic. Showcase presentations will feature medical technologies that deliver improved value in ten transformational themes identified through a survey of leading manufacturers, investors and health care providers.

More information:
About AdvaMed 2015 –
AdvaMed 2015: The MedTech Conference is the leading gathering in North America of global MedTech executives with regulatory, reimbursement, business development, legal, IP, marketing, quality, compliance, and other key responsibilities. Along with industry leaders, the international conference attracts business development professionals, investors, policy-makers, members of the media, legal experts, consultants, distributors, and other important stakeholders.

More that 2.500 attendees will network, conduct business, gain access to capital and share insights in San Diego from October 5-7. The conference also features world-class plenary speakers, networking and business development opportunities.

(BOSTON, MA) —Aldatu Biosciences, a biotechnology company developing gold standard molecular diagnostic assays and based real-time PCR, today announced it has been awarded a $3 Million Direct-to-Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). The award will fund the continued advancement of the company’s proprietary PANDAA™ technology platform and its specific application to the first universal, pan-filovirus detection and differentiation of Ebolavirus and Marburgvirus, the causative agents of Ebola Virus Disease and Marburg Virus Disease.

There is an urgent global unmet market need for a standardized, commercially available pan-species filovirus test that is accessible to resource-limited settings, especially considering the growing reach of the filovirus family as evidenced by the first-ever outbreak in Tanzania that was reported on March 21, 2023.  With a case fatality rate of 88%, Marburg is one of the deadliest of the hemorrhagic fevers. The WHO reported that the 2014-2016 Ebola epidemic in West Africa generated more than 28,000 cases and more than 11,000 deaths in Guinea, Liberia, and Sierra Leone and the CDC reported that more than $3.6 billion was spent to fight the epidemic.

Challenges associated with filovirus biology have previously limited the performance of qPCR in filovirus diagnostics. Many filovirus tests are lab-developed tests and are not available for broad commercial use.  Also, current RT-PCR LDTs are only able to detect regionally endemic clades.